Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
Entinostat-d4, Not available
Application Notes
Useful research chemical for a range of applications
Hazard Compound
No -Refer MSDS for accurate information
Entinostat-d4 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Entinostat-d4 usage and description
Entinostat D4 is a deuterated form of Entinostat, a small molecule drug being investigated for its potential use in cancer therapy. It is an orally administered, class I-selective histone deacetylase (HDAC) inhibitor that works by inhibiting the activity of HDAC enzymes, which are involved in the regulation of gene expression. By inhibiting these enzymes, Entinostat D4 is able to promote the expression of certain genes that are involved in the regulation of cell growth and differentiation.
In preclinical studies, Entinostat D4 has demonstrated anti-tumor activity in a variety of cancer cell lines, including breast, lung, colon, and prostate cancer. It has also been shown to enhance the activity of other cancer therapies, such as chemotherapy and immunotherapy.
Chemically, Entinostat D4 is a deuterated analog of Entinostat, which means that it contains four deuterium atoms instead of hydrogen atoms. The incorporation of deuterium into the molecule can improve its pharmacokinetic properties, such as its bioavailability and half-life, which can enhance its efficacy and reduce the risk of toxicity.
Overall, Entinostat D4 is a promising drug candidate for the treatment of cancer, and ongoing clinical trials are currently underway to evaluate its safety and efficacy in humans.
